Aktuelles & Neues der YM Biosciences Inc.
YM BioSciences Announces Nimotuzumab Results in Advanced Triple-Negative Breast Cancer Model Presented at AACR-NCI-EORTC Meeting
18. November 2009MISSISSAUGA, Canada – November 18, 2009 – YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various...
YM BioSciences Reports CYT997 Oral Vascular Disrupting Agent Results Presented at AACR-NCI-EORTC Meeting
17. November 2009MISSISSAUGA, Canada – November 17, 2009 – YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various...
YM BioSciences Reports Fiscal First Quarter 2010 Operational and Financial Results
12. November 2009MISSISSAUGA, Canada – November 11, 2009 – YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various...
Ym Biosciences Reports Positive Nimotuzumab Four-Year Survival Data Presented at Astro 2009
03. November 2009Follow-On Results from a Randomized Phase IIb Head & Neck Trial Demonstrate Efficacy of Nimotuzumab Without Severe, Class-Associated Toxicities
YM Biosciences Reports Additional Results From Nimotuzumab Phase III Study in Children With Glioma Presented by Oncoscience Ag
30. Oktober 2009On 5:30 pm EDT, Thursday October 29, 2009